Current screening methods involve a blood check to check on for prostate particular antigen, an enzyme produced by the prostate. However the PSA check is controversial. A higher level does not usually indicate prostate cancer plus some experts suggest a growth in PSA is more significant than a consistently high PSA. A high PSA level can also indicate benign prostate conditions. Primarily, we envision this new test could be utilized as a health supplement to PSA. A physician might suggest a patient with an elevated PSA have this check before a biopsy to raised determine whether it’s a cancerous or benign condition. Later on, I think this could replace PSA, says business lead study author Arul Chinnaiyan, M.D., Ph.D., the S.P. Hicks Collegiate Professor of Pathology at the U-M Medical College.GAAP net income of $3.7 million, or $0.11 per diluted talk about for the second quarter of 2014. Net gain on an modified non-GAAP basis in the second quarter of 2015 was $7.4 million or $0.22 per diluted share, compared to adjusted net gain of $7.2 million or $0.22 per diluted share for 2014. For a reconciliation of U.S. GAAP net gain and income per diluted share as reported to adjusted net income and earnings per diluted share for the 2015 and 2014 reporting periods, please see Tables 2 and 3 at the final end of this news release. Beginning in the second quarter 2015, AMRI implemented an updated non-GAAP description, which includes the impact of money interest expenditure and excludes the influence of non-cash stock-based compensation, both which got previously been excluded and included, respectively in the ongoing firm;s calculations of the non-GAAP financial measures.